It is an important ethical concern about the accessibility of life-saving genetic treatments. The case of Kalydeco for CF shows the power of precision medicine, but as you pointed out, its high-cost limits access for many patients. This raises the fundamental question that, should healthcare prioritize profit, or should life-saving treatments be a universal right? One possible solution is government subsidies or pharmaceutical pricing regulations to ensure that all patients can access these advancements.
Your point about the long-term impact of gene therapies is also critical. Some gene therapies involve permanent DNA modifications, and unintended consequences could emerge years later.
Your point about the long-term impact of gene therapies is also critical. Some gene therapies involve permanent DNA modifications, and unintended consequences could emerge years later.